Name of study: 
Exclaim-2

Targeted disease: 
Lung Cancer

Purpose of study:
To compare the efficacy of TAK-788 as first-line treatment with that of platinum-based chemotherapy in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbor epidermal growth factor receptor (EGFR) exon 20 insertion mutations.

Is this a pre- or post- market study?: 
N/A

Is the study of a controlled or observational design? 
Controlled

What is the funding source?: 
Takeda

Where is the study being conducted?
Multi-Center Trial

Lead Institution:
There is no lead institution.

City and State: 
Nationwide

When the study is being conducted: 
Start Date: 1/2021
End date: 6/2022

What website should a person use to register for the study?
https://www.exclaimstudy.com/ 

Who should a person contact to register for the study?
N/A

Who is sponsoring this study?
N/A

What is the identifier for this study on ClinicalTrials.gov?
NCT04129502 

Page last updated: November 9, 2020

No upcoming events near you